Updated FDA policy could help up to 1.8 million HF patients | Hydroxyurea & SCA

Expanded FDA labeling for sacubitril/valsartan could make a massive impact on patient care in the next three years.

The new analysis, published in Blood Advances, examined the impact of hydroxyurea treatment among children and young adults.

The classifier was developed using imaging data from nearly 2,000 patients. 

The American College of Cardiology has published a thorough analysis of the proposed 2022 Medicare Physician Fee Schedule, making many recommendations and comments related to the future of patient care. 

More and more physicians are performing clinical work on a part-time basis, and it might have a negative impact on patient care. 

The new solutions were designed to help users during diagnostic, interventional and endovascular procedures. 

Nearly 3 million Americans gained healthcare coverage during the special enrollment period (SEP) created by President Joe Biden, the White House announced.

The long-term impacts of COVID-19 infection aren’t well known, and the National Institutes of Health (NIH) plans to change that.